SEC Filings
ARK Reports About 7% Of Absci — Its Stake Carries No Control Aim
ARK Genomic Revolution ETF was the only client with an interest above 5% in the reported shares.
Absci (ABSI) news from Bullished: SEC filings, earnings, insider trades and deals, explained in plain English with links to the source documents.
SEC Filings
ARK Genomic Revolution ETF was the only client with an interest above 5% in the reported shares.
Markets
Research spending rose as Absci advanced its own drug programs, with interim hair-regrowth data expected in December.
Earnings
December's interim results will assess early activity, while management plans to use the full 26-week results to choose late-stage doses.
SEC Filings
The AI drug developer expects hair-regrowth results in December and appointed a former Galderma executive as commercial chief.